Interestingly, Cd38 expression was notably elevated in effector CD8+ T cells from the Srsf1–/– mice group (Fig. 2f–i) and CD38+CD8+T cells also conferred more cytotoxic effects (Fig. 2j), which was previously reported to be an activated phenotype.22,23 Recent studies indicate that tumor-infiltrating CD38+CD8+ T cells respond more effectively to anti-PD-1 therapy.23 This prompted us to investigate whether SRSF1 knockdown in T cells could enhance immunotherapy by increasing the infiltration of effector CD38+CD8+ T cells. Here, SRSF1 is linked to neoplasm.